Health News Releases

  • Today December 21
October 06, 2017 15:25
Seattle Genetics and Takeda Announce Publication in Blood of Final Long-Term Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Seattle Genetics, Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced final data from the ADCETRIS (brentuximab vedotin) pivotal Phase 2 clinical trial in relapsed
October 06, 2017 11:30
Bringing Healthcare Home - The Radar Health Monitor That Kyoto University's Center of Innovation and Panasonic Developed Gets a Major Upgrade
In early 2016, researchers from Kyoto University‘s Center of Innovation and Panasonic Corporation developed a radar-based device that could instantaneously and accurately measure the body’s vital sign
SELVAS Healthcare's AI-based Body Composition Analyzer ACCUNIQ BC380
October 02, 2017 17:00
SELVAS Healthcare Launches AI-based Body Composition Analyzer ‘ACCUNIQ BC380’ Worldwide
SELVAS Healthcare has launched a next generation body composition analyzer ACCUNIQ BC380. ACCUNIQ BC380 is a next-generation intelligent body composition analyzer, which reflects the digital healt
October 02, 2017 14:56
Ferring Appoints Klaus Dugi as Executive Vice President and Chief Medical Officer
Ferring Pharmaceuticals announced today that Professor Klaus Dugi has been appointed Executive Vice President and Chief Medical Officer, effective immediately. He will be responsible for Global Med
September 29, 2017 13:25
Takeda to Feature ALUNBRIG™ (brigatinib) Data from Pivotal Phase 2 ALTA Trial at 18th World Conference on Lung Cancer
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the company will present four company-sponsored abstracts, including one oral presentation, at the 18th World Conference on Lung
September 28, 2017 22:05
Replicor Announces Publication of its REP 301 Study in HBV / HDV Co-Infection in The Lancet Gastroenterology & Hepatology
Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announced tod
September 27, 2017 13:05
European Commission Approves Symtuza® for the Treatment of HIV-1 In Adults and Adolescents in Europe
Janssen-Cilag International NV (Janssen) today announced that the European Commission has approved the use of Symtuza® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF])[1], a once
September 26, 2017 13:25
22nd Century Now Free of Restrictive License Agreement with British American Tobacco
22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, is pleased to announce that the 2013 Research License and Commercial Option Agr
September 21, 2017 10:50
6th Annual World Patient Safety, Science & Technology Summit to Be Held in London, England
The Patient Safety Movement Foundation (PSMF) announces that the 6th Annual World Patient Safety, Science & Technology Summit will take place in London on February 23-25, 2018. Rt. Hon. Jeremy Hunt MP
September 20, 2017 18:05
Biosafe Defenses LLC Announces a New Groundbreaking Disinfectant after 10 Years of Research
Biosafe Defenses LLC (formerly Biosafe Technologies LLC), the world leader in the creation of an entirely new class of light-activated disinfectants, antibacterials and biocides for the home, hospital
September 19, 2017 13:10
IPF World Week 2017: Boehringer Ingelheim helps healthcare professionals to ‘listen for the sounds of IPF’
IPF is a progressive and debilitating disease which causes continual and irreversible damage to the lungs.1 Early diagnosis is vital because without appropriate medical intervention, the opportunity t
September 18, 2017 17:15
Bioventus Announces First Patients Enrolled in BONES Study for EXOGEN®
Bioventus, a global leader in orthobiologics, today announced the first patients have been enrolled in its BONES (Bioventus Observational Non-interventional EXOGEN Studies) clinical development progra
September 18, 2017 16:45
CHMP positive opinion to include RE-CIRCUIT® data for atrial fibrillation patients undergoing catheter ablation in Pradaxa® Summary of Product Characteristics
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for an update to the European Summary of Product Characteristics (SmPC) o
September 18, 2017 10:10
Two New Innovative Swiss Made EDOF IOLs for Cataract Surgery
The company Swiss Advanced Vision (SAV-IOL SA) announced today the launch of LUCIDIS and EDEN, two new intraocular lenses (IOLs) for the cataract surgery, both using the Instant Focus EDOF patented te
September 14, 2017 16:30
Kaneka Eurogentec Announces the Construction of a New Large Scale Pharmaceutical Grade Biologics Manufacturing Facility
Kaneka Eurogentec, a custom service and FDA inspected contract development and manufacturing organization (CDMO), announced today that its board has approved the construction of a new state of-the-art
September 14, 2017 15:30
Life Line Screening Expands Product Base to DNA, Clinical Trials
Life Line Screening, a leader in community-based preventive healthcare, is deepening its delivery model of face-to-face patient care to provide access to advanced precision medicine through DNA testin
September 12, 2017 15:00
Safety and efficacy results from the INJOURNEY™ trial investigating OFEV® (nintedanib) with add-on pirfenidone provide new data to support nintedanib’s key role in IPF
Results from the INJOURNEY™ trial, investigating the use of nintedanib in combination with pirfenidone in treating idiopathic pulmonary fibrosis (IPF), have just been published in the American Journal
September 08, 2017 10:26
Boehringer Ingelheim and Gubra collaborate to develop next generation obesity treatments
Boehringer Ingelheim and Gubra announce a collaboration and license agreement for the development of novel peptide compounds to treat obesity. The collaboration will bring together Gubra’s expertise i
September 07, 2017 17:40
LAC-Shield™, Morinaga Milk's New “Immunogenics” Ingredient, Offers Manufacturers Clinically Tested Immune Benefits and Shelf Stability
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced that its recently launched “Immunogenics” ingredient LAC-Shield will now be marketed overseas.
September 06, 2017 13:30
Study Evaluates Performance of Masimo iSpO2® Rx Smart Device-Paired Pulse Oximeter in Screening Newborns for Critical Congenital Heart Disease
Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers in Maastricht, The Netherlands evaluated the performance of Masimo iSpO2® Rx in screening newborns
Ammi Aqua filler
September 04, 2017 17:22
Beautiful Korea Co., Ltd. to enter overseas market with hyaluronic acid (HA) Ammi filler for anti-aging
Beautiful Korea Co., Ltd. (CEO:Byeong Ook Seung) received great praise from abroad for Ammi filler, which was launched in October 2016 and has since been distinguished as a representative hyaluronic a
August 31, 2017 10:40
GN Hearing Launches ReSound ENZO 3D™ and Beltone Boost Max™ - Bringing its New Hearing Care Experience to People with Severe to Profound Hearing Loss
Today, GN Hearing announced the launch of ReSound ENZO 3D™, and the corresponding Beltone Boost Max™, which brings the renowned benefits of ReSound LiNX 3D™ and Beltone Trust™ to people with severe to
August 29, 2017 17:40
Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH
Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly kn
August 29, 2017 13:55
Study Evaluates Utility of Masimo SpHb® During High-Blood-Loss Oncosurgery
Masimo (NASDAQ:MASI) announced today the findings of a recently published study in which researchers in New Delhi, India evaluated the utility of Masimo SpHb®, noninvasive, continuous hemoglobin measu
August 28, 2017 09:30
Pradaxa® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple therapy with warfarin in atrial fibrillation patients undergoing stent placement
The RE-DUAL PCI™ trial explored anticoagulation with Pradaxa® (dabigatran etexilate) dual therapy without aspirin in non-valvular atrial fibrillation (AF) patients following percutaneous coronary inte
25 per page50 per page75 per page100 per page